

**Table 14-4.01**  
**Summary of Planned Exposure to Study Drug, as of End of Study**

	Completers at Week 24			Safety Population [1]		
	Placebo (N=60)	Xanomeline		Placebo (N=86)	Xanomeline	
		Low Dose (N=28)	High Dose (N=30)		Low Dose (N=84)	High Dose (N=84)
Average daily dose (mg)	n	60	28	30	86	84
	mean	0.0	54.0	77.0	0.0	54.0
	std	0.00	0.00	0.58	0.00	0.00
	median	0.0	54.0	76.9	0.0	54.0
	min	0.0	54.0	76.1	0.0	54.0
	max	0.0	54.0	78.6	0.0	78.6
Cumulative dose at end of study [2]	n	60	28	30	86	84
	mean	0.0	9918.6	14089.5	0.0	5347.3
	std	0.00	603.84	481.01	0.00	3680.35
	median	0.0	9936.0	14080.5	0.0	4455.0
	min	0.0	7884.0	12960.0	0.0	108.0
	max	0.0	11448.0	15417.0	0.0	15417.0

[1] Includes completers and early terminators.

[2] End of Study refers to week 26/Early Termination.

Source: C:\cdisc\_pilot\PROGRAMS\DRAFT\TFLs\adsl12.sas

21:02 Monday, June 26, 2006